168 related articles for article (PubMed ID: 1784628)
1. Inhibition of glycemic and hormonal responses after repetitive sucrose and starch loads by different doses of the alpha-glucosidase inhibitor miglitol (BAY m 1099) in man.
Lembcke B; Fölsch UR; Gatzemeier W; Ebert R; Siegel E; Creutzfeldt W
Pharmacology; 1991; 43(6):318-28. PubMed ID: 1784628
[TBL] [Abstract][Full Text] [Related]
2. Inhibition of sucrose- and starch-induced glycaemic and hormonal responses by the alpha-glucosidase inhibitor emiglitate (BAY o 1248) in healthy volunteers.
Lembcke B; Fölsch UR; Gatzemeier W; Lücke B; Ebert R; Siegel E; Creutzfeldt W
Eur J Clin Pharmacol; 1991; 41(6):561-7. PubMed ID: 1815967
[TBL] [Abstract][Full Text] [Related]
3. Postprandial glycemic control, hormonal effects and carbohydrate malabsorption during long-term administration of the alpha-glucosidase inhibitor miglitol.
Lembcke B; Diederich M; Fölsch UR; Creutzfeldt W
Digestion; 1990; 47(1):47-55. PubMed ID: 2292349
[TBL] [Abstract][Full Text] [Related]
4. Effect of Miglitol (Bay m1099), a new alpha-glucosidase inhibitor, on glucose, insulin, C-peptide and GIP responses to an oral sucrose load in patients with post-prandial hypoglycaemic symptoms.
Renard E; Parer-Richard C; Richard JL; Jureidini S; Orsetti A; Mirouze J
Diabete Metab; 1991; 17(3):355-62. PubMed ID: 1884880
[TBL] [Abstract][Full Text] [Related]
5. Reduction of postprandial blood glucose by the alpha-glucosidase inhibitor Miglitol (BAY m 1099) in type II diabetes.
Heinz G; Komjati M; Korn A; Waldhäusl W
Eur J Clin Pharmacol; 1989; 37(1):33-6. PubMed ID: 2687007
[TBL] [Abstract][Full Text] [Related]
6. Dose-dependent efficacy of miglitol, an alpha-glucosidase inhibitor, in type 2 diabetic patients on diet alone: results of a 24-week double-blind placebo-controlled study.
Drent ML; Tollefsen AT; van Heusden FH; Hoenderdos EB; Jonker JJ; van der Veen EA
Diabetes Nutr Metab; 2002 Jun; 15(3):152-9. PubMed ID: 12173729
[TBL] [Abstract][Full Text] [Related]
7. Intestinal and metabolic responses to an alpha-glucosidase inhibitor in normal volunteers.
Holt PR; Thea D; Yang MY; Kotler DP
Metabolism; 1988 Dec; 37(12):1163-70. PubMed ID: 3057329
[TBL] [Abstract][Full Text] [Related]
8. Metabolic consequences of the alpha-glucosidase inhibitor BAY-M-1099 given to nondiabetic and diabetic rats fed a high-carbohydrate diet.
Madar Z
Am J Clin Nutr; 1989 Jan; 49(1):106-11. PubMed ID: 2643291
[TBL] [Abstract][Full Text] [Related]
9. alpha-Glucosidase inhibition by miglitol in NIDDM patients.
Kingma PJ; Menheere PP; Sels JP; Nieuwenhuijzen Kruseman AC
Diabetes Care; 1992 Apr; 15(4):478-83. PubMed ID: 1499461
[TBL] [Abstract][Full Text] [Related]
10. Long-term titrated-dose alpha-glucosidase inhibition in non-insulin-requiring Hispanic NIDDM patients.
Johnston PS; Feig PU; Coniff RF; Krol A; Davidson JA; Haffner SM
Diabetes Care; 1998 Mar; 21(3):409-15. PubMed ID: 9540024
[TBL] [Abstract][Full Text] [Related]
11. Miglitol may have a blood glucose lowering effect unrelated to inhibition of alpha-glucosidase.
Joubert PH; Foukaridis GN; Bopape ML
Eur J Clin Pharmacol; 1987; 31(6):723-4. PubMed ID: 3549325
[TBL] [Abstract][Full Text] [Related]
12. Miglitol (Bay m 1099) has no extraintestinal effects on glucose control in healthy volunteers.
Sels JP; Nauta JJ; Menheere PP; Wolffenbuttel BH; Nieuwenhuijzen Kruseman AC
Br J Clin Pharmacol; 1996 Oct; 42(4):503-6. PubMed ID: 8904624
[TBL] [Abstract][Full Text] [Related]
13. The effect of acarbose and miglitol (BAY-M-1099) on postprandial glucose levels following ingestion of various sources of starch by nondiabetic and streptozotocin-induced diabetic rats.
Madar Z
J Nutr; 1989 Dec; 119(12):2023-9. PubMed ID: 2695605
[TBL] [Abstract][Full Text] [Related]
14. A new alpha-glucosidase inhibitor (Bay-m-1099) reduces insulin requirements with meals in insulin-dependent diabetes mellitus.
Kennedy FP; Gerich JE
Clin Pharmacol Ther; 1987 Oct; 42(4):455-8. PubMed ID: 3311550
[TBL] [Abstract][Full Text] [Related]
15. Regulation of the absorption of dietary carbohydrate in man by two new glycosidase inhibitors.
Taylor RH; Barker HM; Bowey EA; Canfield JE
Gut; 1986 Dec; 27(12):1471-8. PubMed ID: 3804023
[TBL] [Abstract][Full Text] [Related]
16. Miglitol, a new alpha-glucosidase inhibitor.
Sels JP; Huijberts MS; Wolffenbuttel BH
Expert Opin Pharmacother; 1999 Nov; 1(1):149-56. PubMed ID: 11249557
[TBL] [Abstract][Full Text] [Related]
17. [Delayed absorption of carbohydrates in the therapy of Type II diabetes: comparison between dietary (Muesli) and pharmacological (Alpha-glucosidase inhibition) modification].
Willms B; Lübke D; Ahrens K; Arends J
Schweiz Med Wochenschr; 1991 Sep; 121(38):1379-82. PubMed ID: 1656521
[TBL] [Abstract][Full Text] [Related]
18. Effects of 8-wk alpha-glucosidase inhibition on metabolic control, C-peptide secretion, hepatic glucose output, and peripheral insulin sensitivity in poorly controlled type II diabetic patients.
Schnack C; Prager RJ; Winkler J; Klauser RM; Schneider BG; Schernthaner G
Diabetes Care; 1989 Sep; 12(8):537-43. PubMed ID: 2673693
[TBL] [Abstract][Full Text] [Related]
19. The effect of new alpha-glucosidase inhibitors (BAY m 1099 and BAY o 1248) on meal-stimulated increases in glucose and insulin levels in man.
Hillebrand I; Boehme K; Graefe KH; Wehling K
Klin Wochenschr; 1986 Apr; 64(8):393-6. PubMed ID: 3517475
[TBL] [Abstract][Full Text] [Related]
20. Does suppression of postprandial blood glucose excursions by the alpha-glucosidase inhibitor miglitol improve insulin sensitivity in diet-treated type II diabetic patients?
Johnson AB; Taylor R
Diabetes Care; 1996 Jun; 19(6):559-63. PubMed ID: 8725851
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
